These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

213 related articles for article (PubMed ID: 34651447)

  • 1. A Patent Review on SARS Coronavirus Main Protease (3CL
    Chia CSB; Xu W; Shuyi Ng P
    ChemMedChem; 2022 Jan; 17(1):e202100576. PubMed ID: 34651447
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A head-to-head comparison of the inhibitory activities of 15 peptidomimetic SARS-CoV-2 3CLpro inhibitors.
    Vankadara S; Wong YX; Liu B; See YY; Tan LH; Tan QW; Wang G; Karuna R; Guo X; Tan ST; Fong JY; Joy J; Chia CSB
    Bioorg Med Chem Lett; 2021 Sep; 48():128263. PubMed ID: 34271072
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A Patent Review on SARS Coronavirus Papain-Like Protease (PL
    Brian Chia CS; Pheng Lim S
    ChemMedChem; 2023 Aug; 18(16):e202300216. PubMed ID: 37248169
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Structure-Based Optimization of ML300-Derived, Noncovalent Inhibitors Targeting the Severe Acute Respiratory Syndrome Coronavirus 3CL Protease (SARS-CoV-2 3CL
    Han SH; Goins CM; Arya T; Shin WJ; Maw J; Hooper A; Sonawane DP; Porter MR; Bannister BE; Crouch RD; Lindsey AA; Lakatos G; Martinez SR; Alvarado J; Akers WS; Wang NS; Jung JU; Macdonald JD; Stauffer SR
    J Med Chem; 2022 Feb; 65(4):2880-2904. PubMed ID: 34347470
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prioritisation of Compounds for 3CL
    Jukič M; Škrlj B; Tomšič G; Pleško S; Podlipnik Č; Bren U
    Molecules; 2021 May; 26(10):. PubMed ID: 34070140
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Discovery of 9,10-dihydrophenanthrene derivatives as SARS-CoV-2 3CL
    Zhang JW; Xiong Y; Wang F; Zhang FM; Yang X; Lin GQ; Tian P; Ge G; Gao D
    Eur J Med Chem; 2022 Jan; 228():114030. PubMed ID: 34883292
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Identification of 3-chymotrypsin like protease (3CLPro) inhibitors as potential anti-SARS-CoV-2 agents.
    Mody V; Ho J; Wills S; Mawri A; Lawson L; Ebert MCCJC; Fortin GM; Rayalam S; Taval S
    Commun Biol; 2021 Jan; 4(1):93. PubMed ID: 33473151
    [TBL] [Abstract][Full Text] [Related]  

  • 8. What coronavirus 3C-like protease tells us: From structure, substrate selectivity, to inhibitor design.
    Xiong M; Su H; Zhao W; Xie H; Shao Q; Xu Y
    Med Res Rev; 2021 Jul; 41(4):1965-1998. PubMed ID: 33460213
    [TBL] [Abstract][Full Text] [Related]  

  • 9. 3CL Protease Inhibitors with an Electrophilic Arylketone Moiety as Anti-SARS-CoV-2 Agents.
    Konno S; Kobayashi K; Senda M; Funai Y; Seki Y; Tamai I; Schäkel L; Sakata K; Pillaiyar T; Taguchi A; Taniguchi A; Gütschow M; Müller CE; Takeuchi K; Hirohama M; Kawaguchi A; Kojima M; Senda T; Shirasaka Y; Kamitani W; Hayashi Y
    J Med Chem; 2022 Feb; 65(4):2926-2939. PubMed ID: 34313428
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Development of a Fluorescence-Based, High-Throughput SARS-CoV-2 3CL
    Froggatt HM; Heaton BE; Heaton NS
    J Virol; 2020 Oct; 94(22):. PubMed ID: 32843534
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Inhibitors of Coronavirus 3CL Proteases Protect Cells from Protease-Mediated Cytotoxicity.
    Resnick SJ; Iketani S; Hong SJ; Zask A; Liu H; Kim S; Melore S; Lin FY; Nair MS; Huang Y; Lee S; Tay NES; Rovis T; Yang HW; Xing L; Stockwell BR; Ho DD; Chavez A
    J Virol; 2021 Jun; 95(14):e0237420. PubMed ID: 33910954
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The SARS-coronavirus papain-like protease: structure, function and inhibition by designed antiviral compounds.
    Báez-Santos YM; St John SE; Mesecar AD
    Antiviral Res; 2015 Mar; 115():21-38. PubMed ID: 25554382
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Targeting the Dimerization of the Main Protease of Coronaviruses: A Potential Broad-Spectrum Therapeutic Strategy.
    Goyal B; Goyal D
    ACS Comb Sci; 2020 Jun; 22(6):297-305. PubMed ID: 32402186
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Repurposing existing drugs: identification of SARS-CoV-2 3C-like protease inhibitors.
    Chiou WC; Hsu MS; Chen YT; Yang JM; Tsay YG; Huang HC; Huang C
    J Enzyme Inhib Med Chem; 2021 Dec; 36(1):147-153. PubMed ID: 33430659
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Considerations for the discovery and development of 3-chymotrypsin-like cysteine protease inhibitors targeting SARS-CoV-2 infection.
    Vandyck K; Deval J
    Curr Opin Virol; 2021 Aug; 49():36-40. PubMed ID: 34029993
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Protease targeted COVID-19 drug discovery: What we have learned from the past SARS-CoV inhibitors?
    Amin SA; Banerjee S; Gayen S; Jha T
    Eur J Med Chem; 2021 Apr; 215():113294. PubMed ID: 33618158
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Design, synthesis and in vitro evaluation of novel SARS-CoV-2 3CL
    Stille JK; Tjutrins J; Wang G; Venegas FA; Hennecker C; Rueda AM; Sharon I; Blaine N; Miron CE; Pinus S; Labarre A; Plescia J; Burai Patrascu M; Zhang X; Wahba AS; Vlaho D; Huot MJ; Schmeing TM; Mittermaier AK; Moitessier N
    Eur J Med Chem; 2022 Feb; 229():114046. PubMed ID: 34995923
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Peptidomimetic α-Acyloxymethylketone Warheads with Six-Membered Lactam P1 Glutamine Mimic: SARS-CoV-2 3CL Protease Inhibition, Coronavirus Antiviral Activity, and
    Bai B; Belovodskiy A; Hena M; Kandadai AS; Joyce MA; Saffran HA; Shields JA; Khan MB; Arutyunova E; Lu J; Bajwa SK; Hockman D; Fischer C; Lamer T; Vuong W; van Belkum MJ; Gu Z; Lin F; Du Y; Xu J; Rahim M; Young HS; Vederas JC; Tyrrell DL; Lemieux MJ; Nieman JA
    J Med Chem; 2022 Feb; 65(4):2905-2925. PubMed ID: 34242027
    [TBL] [Abstract][Full Text] [Related]  

  • 19. An Updated Review on SARS-CoV-2 Main Proteinase (M
    Sabbah DA; Hajjo R; Bardaweel SK; Zhong HA
    Curr Top Med Chem; 2021; 21(6):442-460. PubMed ID: 33292134
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Evaluation of SARS-CoV-2 3C-like protease inhibitors using self-assembled monolayer desorption ionization mass spectrometry.
    Gurard-Levin ZA; Liu C; Jekle A; Jaisinghani R; Ren S; Vandyck K; Jochmans D; Leyssen P; Neyts J; Blatt LM; Beigelman L; Symons JA; Raboisson P; Scholle MD; Deval J
    Antiviral Res; 2020 Oct; 182():104924. PubMed ID: 32896566
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.